Navigation Links
Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in First-Line Metastatic Colorectal Cancer
Date:9/24/2009

THOUSAND OAKS, Calif., Sept. 24 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 '203' trial evaluating Vectibix(R) (panitumumab) administered in combination with FOLFOX (an oxaliplatin-based chemotherapy) as the first-line treatment of metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved median progression-free survival (PFS) by 1.6 months (9.6 versus 8.0 months for patients treated with FOLFOX alone, (hazard ratio 0.80; p=0.02)) in patients with KRAS wild-type mCRC (primary endpoint). The results were presented at the 2009 ECCO 15 - ESMO 34 European Multidisciplinary Congress in Berlin, Germany (Abstract Number 10LBA).

Further, the addition of Vectibix to chemotherapy also improved response rate in the KRAS wild-type patient population as measured by blinded central review (55 percent versus 48 percent in the FOLFOX only arm).

"I am very pleased with the outcome of this high quality trial which demonstrated that Vectibix improved progression-free survival and appeared to be well tolerated as a first-line metastatic colorectal cancer treatment in a selected patient population," said Jean-Yves Douillard, director Clinical and Translational Research, Medical Oncology Branch, Centre R Gauducheau, France and the study's principal investigator. "This is the first prospective Phase 3 data to demonstrate the importance of KRAS mutation as a predictive biomarker for Vectibix treatment in the first-line setting, providing definitive support for the use of the KRAS biomarker for selection of patients eligible for anti-EGFR therapy."

Importantly, in patients with tumors harboring activating KRAS mutations, PFS was significantly inferior in the V
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Vectibix(R) in Combination With Chemotherapy Significantly Improves Progression-Free Survival in Second-Line Metastatic Colorectal Cancer
2. Vectibix(R) Significantly Improved Progression-Free Survival in Second-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer
3. Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer
4. In Vitro Study of Adamas Pharmaceuticals Triple Combination Antiviral Drug Therapy Shows Activity Against Drug-Resistant Influenza Viruses
5. Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
6. Adamas Pharmaceuticals Signs CRADA With U.S. Navy to Conduct Preclinical Studies of Triple-Combination Antiviral Drug Therapy for Influenza A, Including the Novel H1N1 Pandemic Strain
7. Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)
8. Schering-Plough Announces U.S. Filing of Mometasone Furoate/Formoterol Fumarate Combination for the Maintenance Treatment of Asthma
9. Tibotec Pharmaceuticals Announces Agreement to Develop and Commercialize a New Fixed-Dose Combination of TMC278 and Truvada(R) With Gilead Sciences
10. Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
11. Access Pharmaceuticals Announces Publication of Thiarabine Combination Data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... PHILADELPHIA , Aug. 21, 2014  ACI ... platform for independent Data Monitoring Committees. ... to 30 percent over industry standard costs and ... an industry leader in committee services. ... member recruitment and contracting, charter development, statistical programming ...
(Date:8/21/2014)... FLORHAM PARK, N.J. , Aug. 21, 2014 ... specialty pharmacy group purchasing organization (GPO), is pleased ... (Aurora) to collaborate on a host of innovative ... will help Aurora deliver enhanced therapy management services ... Therapy Management (OTM) system. Aurora will ...
(Date:8/21/2014)... 21, 2014  The board of directors of VirtualScopics, ... of clinical trial imaging solutions, today announced that ... officer, effective immediately.  Mr. Groff has held the role ... joined VirtualScopics in January 2006 as an accounting manager ... "When the board of VirtualScopics asked Jim to ...
Breaking Medicine Technology:ACI Clinical: Innovation and Savings in Data Safety Monitoring Committees 2Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 2Aurora Health Care Partners with Armada Health Care to Deliver Added Pharmacy Capabilities to Specialty Patients 3VirtualScopics, Inc. Names James Groff Chief Financial Officer 2VirtualScopics, Inc. Names James Groff Chief Financial Officer 3VirtualScopics, Inc. Names James Groff Chief Financial Officer 4
... but,Underscore Need for Improved Patient Communication, Lifestyle,Management ... Elevated,Blood Pressure, NEW YORK, May 19, 2007 ... Harris Interactive(R) for the Hypertension Education,Foundation (HEF) ... Inc. (ASH) Twenty-Second Annual Scientific Meeting,and Exposition ...
... SAN FRANCISCO--(BUSINESS WIRE)--May 21, 2007 - Medical,professionals ... problem of,hospital-acquired gram-negative pneumonia may have a ... candidate being,developed by Nektar Therapeutics (Nasdaq:NKTR)., Results ... the use of,NKTR-061 (Inhaled Amikacin) to treat ...
Cached Medicine Technology:Hypertension Education Foundation Survey Results Announced At,American Society For Hypertension Annual Meeting Suggests Improved,Control Of High Blood Pressure, But Misconceptions Still Exist 2Hypertension Education Foundation Survey Results Announced At,American Society For Hypertension Annual Meeting Suggests Improved,Control Of High Blood Pressure, But Misconceptions Still Exist 3Hypertension Education Foundation Survey Results Announced At,American Society For Hypertension Annual Meeting Suggests Improved,Control Of High Blood Pressure, But Misconceptions Still Exist 4Hypertension Education Foundation Survey Results Announced At,American Society For Hypertension Annual Meeting Suggests Improved,Control Of High Blood Pressure, But Misconceptions Still Exist 5Hypertension Education Foundation Survey Results Announced At,American Society For Hypertension Annual Meeting Suggests Improved,Control Of High Blood Pressure, But Misconceptions Still Exist 6Hypertension Education Foundation Survey Results Announced At,American Society For Hypertension Annual Meeting Suggests Improved,Control Of High Blood Pressure, But Misconceptions Still Exist 7Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 2Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 3Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 4Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 5Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 6Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 7Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 8Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 9Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 10Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 11
(Date:8/22/2014)... Renal artery stenting to open blockages in ... historically been excluded from modern clinical trials, according ... in Catheterization and Cardiovascular Interventions today ... (SCAI). , University Hospitals Case Medical Center,s Sahil ... Professor of Medicine, Case Western Reserve University School ...
(Date:8/22/2014)... August 22, 2014 Home Care ... in-home care for seniors, is proud to announce the ... The upcoming webinar will feature Dr. Suzanne Steinbaum, attending ... Hill Hospital in New York City, National Spokesperson for ... The webinar will cover the issues surrounding women and ...
(Date:8/22/2014)... Aug. 22, 2014 (HealthDay News) -- Many children get ... vaccination, but there are a number of ways that ... an expert suggests. The first step is to ... vaccinations help protect their health, said Rita John, director ... Columbia University School of Nursing in New York City. ...
(Date:8/22/2014)... few years, several breakthrough treatments have become available ... may benefit from these treatments can be pre-identified ... cancer. For example, patients whose lung cancer is ... significant benefit from the drug crizotinib, which targets ... attempting to replicate this success by matching different ...
(Date:8/22/2014)... who need surgery for facial pain caused by trigeminal ... used, reports a study in the September issue of ... Congress of Neurological Surgeons . The journal is ... part of Wolters Kluwer Health . , Percutaneous ... lower cost than other types of surgical treatments for ...
Breaking Medicine News(10 mins):Health News:UH Case Medical Center's Dr. Parikh authors SCAI paper on renal artery stenosis treatment 2Health News:UH Case Medical Center's Dr. Parikh authors SCAI paper on renal artery stenosis treatment 3Health News:Home Care Assistance of Centennial to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 2Health News:Home Care Assistance of Centennial to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 3Health News:Simple Steps Make Shots Less Scary for Kids, Nurse Says 2Health News:Online screening for rare lung cancer subtypes opens door to new kind of clinical trial 2Health News:Online screening for rare lung cancer subtypes opens door to new kind of clinical trial 3Health News:Online screening for rare lung cancer subtypes opens door to new kind of clinical trial 4Health News:More common procedures for painful facial tics carry high costs, reports study in Neurosurgery 2
... Hospira, Inc. (NYSE: HSP ), a leading global ... host a conference call to discuss its second-quarter 2009 results on ... , , The company will release its second-quarter 2009 results ... conference call. , , A live webcast of the ...
... military readiness, harms the health of soldiers and veterans, ... of Defense and Veterans Affairs, these agencies should implement ... goal of a tobacco-free military, says a new report ... phase in a ban on tobacco use in the ...
... Ormco Corporation, a subsidiary of Danaher Corporation (NYSE: ... jury verdict in its patent infringement case against Align Technology, ... to straighten teeth. The jury unanimously found that Align,s ... a patent held by Ormco. The claims at issue ...
... 26 Warner Chilcott Limited announced today that it will ... Meeting") and a Special Court-Ordered Meeting of Shareholders (the "Special ... the Company,s shareholders will be asked to vote in favor ... Company from Bermuda to Ireland. Subject to shareholder approval ...
... Calif., June 26 Align Technology, Inc. (Nasdaq: ... against Align in a lawsuit brought by Ormco Corporation (Ormco) ... for the Central District of California (District Court). Ormco alleged ... non-infringement, invalidity, as well as unenforceability of the patent. ...
... R.I., June 26 CVS Caremark (NYSE: ... been named as one of the nation,s leading corporations for innovative ... their families to make better choices about their own health and ... ) , , CVS Caremark received the ...
Cached Medicine News:Health News:DOD, VA should take stronger steps to combat tobacco use in military, veteran populations 2Health News:DOD, VA should take stronger steps to combat tobacco use in military, veteran populations 3Health News:Jury Renders Verdict for Ormco - Align's Invisalign(R) Product Infringes Ormco Patent 2Health News:Warner Chilcott to Hold 2009 Annual General Meeting of Shareholders and Special Court-Ordered Meeting of Shareholders 2Health News:Align Technology Announces Jury Verdict in Patent Litigation With Ormco Corporation 2Health News:CVS Caremark Recognized with Gold Award from National Business Group on Health for Promoting Healthy Lifestyles for Employees 2Health News:CVS Caremark Recognized with Gold Award from National Business Group on Health for Promoting Healthy Lifestyles for Employees 3
... Designed in collaboration with Dr. George ... the Ojemann Cortical Stimulator is the ... procedures. This portable, constant current unit ... settings suitable for use in the ...
... Integra Epilepsy cortical strip electrodes are ... intracranial placement through a burr hole. ... tunneling and enables quick and secure ... Like all Integra Epilepsy electrode designs, ...
...
... URISYS 2400 is designed for laboratories looking ... and convenience in system operation in terms ... and extended calibration and on-board stability., ... system providing enhanced walk-away capability for medium ...
Medicine Products: